A team at Mayo Clinic has developed a promising six-marker methylated DNA panel to detect endometrial cancer with high sensitivity using self-collected vaginal fluid samples, potentially reducing the need for invasive endometrial biopsies.

The study, presented at the Society of Gynecologic Oncology 2025 Annual Meeting, demonstrated 89% sensitivity for detecting endometrial cancer with 85% specificity, particularly excelling for higher-grade cancers. The clinical validation included two cohorts, and the final 6-MDM panel achieved an area under the curve (AUC) of 0.93. The study supports further development of a vaginal fluid-based test for endometrial cancer.